Brainsway Ltd.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BWAY in the last 30 days.
See all $BWAY insider activity →Bumble (BMBL) surged 56.7% to $5.96 after agreeing to a $6.05/share private takeover by Ithaca Holdings. Other movers: Fermi (FRMI) +22.5%, Enerflex (EFXT) +13.6%, BigBear.ai (BBAI) +9.1%, MongoDB (MDB) +6.8%, Xtend AI (XTND) +6.6%.
BrainsWay Ltd. (BWAY) reports that its SWIFT Accelerated Deep TMS protocol is now covered by U.S. medical policies for over 70 million lives, indicating growing payer acceptance. The company attributes this to favorable policy momentum for Deep TMS in treating MDD and OCD, following prior FDA clearances.
BrainsWay (BWAY) reported 1H GAAP EPS of $0.12 and revenue of $32.64M, up 35.0% Y/Y. As of June 30, 2026, the company had $62.4M in cash and an accumulated deficit of $85.8M. Shares rose 1.51%.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BWAY (Brainsway Ltd.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BWAY coverage spans earnings, financial news and regulation.
Expanded coverage suggests revenue growth.
Expanded coverage could increase patient volume and revenue.
Earnings beat expectations, modest revenue growth may support a slight price rise.
Strong top-line growth and higher margins suggest upside potential, but modest guidance raise tempers enthusiasm.
Positive early‑stage clinical data may boost investor optimism for future FDA clearance and larger trials.
AlphAI scores every news story that mentions BWAY with an AI model for sentiment and relevance, and aggregates insider trades from Brainsway Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bumble (BMBL) surged 56.7% to $5.96 after agreeing to a $6.05/share private takeover by Ithaca Holdings. Other movers: Fermi (FRMI) +22.5%, Enerflex (EFXT) +13.6%, BigBear.ai (BBAI) +9.1%, MongoDB (MDB) +6.8%, Xtend AI (XTND) +6.6%.
3 min readBrainsWay Ltd. (BWAY) reports that its SWIFT Accelerated Deep TMS protocol is now covered by U.S. medical policies for over 70 million lives, indicating growing payer acceptance. The company attributes this to favorable policy momentum for Deep TMS in treating MDD and OCD, following prior FDA clearances.
1 min readBrainsWay (BWAY) reported 1H GAAP EPS of $0.12 and revenue of $32.64M, up 35.0% Y/Y. As of June 30, 2026, the company had $62.4M in cash and an accumulated deficit of $85.8M. Shares rose 1.51%.
1 min readBrainsWay Ltd. (BWAY) reported Q2 2026 revenue of $17.1M, up 35% YoY, and adjusted EBITDA of $3.5M, more than double YoY. The company shipped a record 125 Deep TMS systems and raised full-year guidance for the second time this year. Operating income and margins also improved significantly, with operating margin expanding to 14% from 5% YoY.
2 min readBrainsWay Ltd. (NASDAQ: BWAY) reported results from a pilot study on its Deep TMS™ technology in patients with depression and early-stage Alzheimer’s disease. The study showed an 83.3% response rate and 50% remission rate in depressive symptoms, with measurable changes in brain activity. The study was published in the Journal of Geriatric Psychiatry and Neurology.
2 min readBrainsWay (BWAY) reported Q2 2026 operating income up 300% to $2.4M, adjusted EBITDA up 141% to $3.5M, and 125 Deep TMS systems shipped, a 42% increase. Remaining performance obligations rose 30% to $80.4M. The company highlighted growth in reimbursement, clinical evidence, and strategic investments in behavioral health platforms.
3 min readBrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.
4 min readBrainsWay Ltd. (NASDAQ, TASE: BWAY) reported Q2 2026 revenue up 35% to $17.1 million. Adjusted EBITDA more than doubled to $3.5 million (20% margin). Remaining performance obligations rose 30% to $80.4 million, and it shipped 125 Deep TMS systems (+42% YoY). The company raised FY2026 revenue guidance to $68-$70 million and Adjusted EBITDA to $13-$14 million.
6 min readBrainsway Ltd. (BWAY) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights Record s econd q uarter 2026 r evenue increased 35% t o $17. 1 m illion, compared with Q2 2025 Adjusted EBITDA more than doubled year-over-year to $3.5 million, with margin expanding t
2 min readA roundup of Monday analyst actions includes Morgan Stanley reiterating Nvidia (overweight) and Broadcom (overweight), with a focus on data center memory-cycle signals. BMO downgraded Charles Schwab to market perform. Cantor reiterated Tesla overweight ahead of earnings. Other calls include price targets for Versigent, Crane, Lumentum, and Apple, plus initiations for BP and TotalEnergies.
6 min read
